Reviva Pharmaceuticals (NASDAQ:RVPH) Upgraded at Roth Capital

Roth Capital upgraded shares of Reviva Pharmaceuticals (NASDAQ:RVPH) to a strong-buy rating in a report issued on Friday,Zacks.com reports.

RVPH has been the subject of a number of other research reports. Roth Mkm initiated coverage on Reviva Pharmaceuticals in a research report on Friday. They set a “buy” rating and a $7.00 price objective for the company. Maxim Group upgraded Reviva Pharmaceuticals from a “hold” rating to a “buy” rating and set a $7.00 price target for the company in a report on Friday. Finally, EF Hutton Acquisition Co. I upgraded Reviva Pharmaceuticals to a “strong-buy” rating in a report on Monday, September 23rd. Four analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat.com, Reviva Pharmaceuticals has a consensus rating of “Buy” and a consensus price target of $11.25.

Reviva Pharmaceuticals Stock Up 0.5 %

RVPH stock opened at $1.88 on Friday. The company has a 50 day moving average of $1.56 and a two-hundred day moving average of $1.29. Reviva Pharmaceuticals has a 12-month low of $0.60 and a 12-month high of $4.83. The company has a market cap of $62.87 million, a price-to-earnings ratio of -1.69 and a beta of -0.12.

Institutional Investors Weigh In On Reviva Pharmaceuticals

A hedge fund recently raised its stake in Reviva Pharmaceuticals stock. Geode Capital Management LLC grew its holdings in Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) by 17.9% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 278,496 shares of the company’s stock after purchasing an additional 42,376 shares during the quarter. Geode Capital Management LLC owned approximately 0.83% of Reviva Pharmaceuticals worth $401,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 63.18% of the company’s stock.

Reviva Pharmaceuticals Company Profile

Reviva Pharmaceuticals Holdings, Inc, a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. The company's lead product candidate comprises brilaroxazine (RP5063) for the treatment of various neuropsychiatric indications, including schizophrenia, bipolar disorder, major depressive disorder, attentiondeficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia and Alzheimer's disease, and Parkinson's disease psychosis; in clinical development respiratory indications, such as pulmonary arterial hypertension and idiopathic pulmonary fibrosis; and in preclinical development for the treatment of psoriasis.